logo-loader
viewMaxCyte Inc

Maxcyte reports 30% revenue growth as key programmes advance through clinical studies

Proactive research analyst Emma Ulker discusses MaxCyte's (LON:MXCT) results for the year to December 2019.

Ulker says the firm delivered a consensus-beating 30% uplift in full-year 2019 revenues to US$21.6mln - underpinned by the release of milestone payments from its commercial partners as programmes advanced through clinical studies and by a 25% five-year revenue compound annualised growth rate (CAGR).

 

Click here to read the latest research update on MaxCyte : Milestones a key contributor to 30% top line growth

Quick facts: MaxCyte Inc

Price: 310 GBX

AIM:MXCT
Market: AIM
Market Cap: £239.2 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MaxCyte Inc named herein, including the promotion by the Company of MaxCyte Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

MaxCyte Inc gearing up for phase I study of potential cancer breakthrough

Doug Doerfler, chief executive of MaxCyte Inc (LON:MXCT), tells Proactive they're in a strong financial position as they prepare for the launch of a phase I clinical trial of a cancer treatment which helps to deploy the body’s own immune defences to combat strains of the killer...

on 23/1/18

2 min read